146118-12-9

Basic information

• Product Name: t-butyl [[1-[N₂-(p-amidinobenzoyl)-N₅-(t-butoxycarbonyl)-L-ornithyl]-4-piperidinyl]oxy]acetate
• Synonyms: t-butyl [[1-[N₂-(p-amidinobenzoyl)-N₅-(t-butoxycarbonyl)-L-ornithyl]-4-piperidinyl]oxy]acetate
• CAS NO: 146118-12-9
• Molecular Weight: 575.706
• Mol File: 146118-12-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: t-butyl [[1-[N₂-(p-amidinobenzoyl)-N₅-(t-butoxycarbonyl)-L-ornithyl]-4-piperidinyl]oxy]acetate(CAS DataBase Reference)
• NIST Chemistry Reference: t-butyl [[1-[N₂-(p-amidinobenzoyl)-N₅-(t-butoxycarbonyl)-L-ornithyl]-4-piperidinyl]oxy]acetate(146118-12-9)
• EPA Substance Registry System: t-butyl [[1-[N₂-(p-amidinobenzoyl)-N₅-(t-butoxycarbonyl)-L-ornithyl]-4-piperidinyl]oxy]acetate(146118-12-9)

Safety Data

• Hazardous Substances Data: 146118-12-9(Hazardous Substances Data)

Upstream product

• 1053734-54-5 [1-((S)-2-Benzyloxycarbonylamino-5-tert-butoxycarbonylamino-pentanoyl)-piperidin-4-yloxy]-acetic acid tert-butyl ester 
• 144412-43-1 t-Butyl 2-(1-benzyloxycarbonyl-4-piperidyl)oxyacetate 
• 144412-03-3 (Piperidin-4-yloxy)-acetic acid tert-butyl ester 
• 15535-95-2 4-(aminoiminomethyl)benzoic acid 
• 95798-23-5 1-(benzyloxycarbonyl)-4-hydroxypiperidine 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 144412-10-2 [1-((S)-2-Amino-5-tert-butoxycarbonylamino-pentanoyl)-piperidin-4-yloxy]-acetic acid tert-butyl ester 
• 7733-29-1 Z-Orn(Boc)-OH 

Downstream Products

• 144412-22-6 [[1-[N₂-(p-amidinobenzoyl)-L-ornithyl]-4-piperidinyl]oxy]acetic acid 

Relevant articles and documents

Low molecular weight, non-peptide fibrinogen receptor antagonists

The tetrapeptide H-Arg-Gly-Asp-Ser-OH (1) (RGDS), representing a recognition sequence of fibrinogen for its platelet receptor GP IIb-IIIa (integrin α(IIb)β3), served as lead compound for the development of highly potent and selective fibrinogen receptor antagonists. Replacement of the N- terminal arginine by p-amidinophenylalanine or the Gly moiety by m- aminobenzoic acid led to compounds which are superior to the lead peptide with regard to activity and selectivity for GP IIb-IIIa vs the closely related vitronectin receptor α(v)β3. By random screening [(p- amidinobenzenesulfonamido)ethyl]-p-phenoxyacetic acid derivatives have been identified as fibrinogen receptor antagonists. Further structure-activity relationship studies culminated in the preparation of N-[N-[N-(p- amidinobenzoyl)-β-alanyl]-L-α-aspartyl]-3-phenyl-L-alanine (29h, Ro 43- 5054) and [[1-[N-(p-amidinobenzoyl)-L-tyrosyl]-4-piperidinyl]oxy]acetic acid (37f, Ro 44-9883), which exhibit very high activity as platelet aggregation inhibitors (IC50s 0.06 and 0.03 μM, respectively, human PRP/ADP) as well as marked selectivity for GP IIb-IIIa vs α(v)β3. Since the activity of 37f in dogs declines according to a two-compartment model with an initial phase having a t( 1/2 ) of 8 min and a second phase with a t( 1/2 ) of 110 min, this compound is a suitable candidate for the development as iv platelet inhibitor.